---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-069123"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:08:37.945029+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer

## Summary
- CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.
- CEO John Butler will serve as interim principal financial officer starting Transition Date.
- Separation agreement provides 12 months base salary, COBRA premium reimbursement, continued equity vesting.
- Severance conditioned on general release of claims and compliance with non-compete and non-solicitation terms.

## SEC filing metadata
- accession: 0001193125-24-069123
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/0001193125-24-069123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/d650653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-069123
- JSON: https://secwatch.observer/filing/0001193125-24-069123.json
- Plain text: https://secwatch.observer/filing/0001193125-24-069123.txt

## Key facts
- Executive change
  John Butler was appointed as interim principal financial officer at Akebia Therapeutics, Inc..
  - Action: appointed
  - Role: interim principal financial officer
  source text: John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/0001193125-24-069123-index.htm
- Executive change
  Ellen Snow changed role as Senior Vice President, Chief Financial Officer and Treasurer at Akebia Therapeutics, Inc..
  - Action: transitioned
  - Role: Senior Vice President, Chief Financial Officer and Treasurer
  source text: On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/0001193125-24-069123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.